Effect of adding a psychological intervention to routine care of common mental disorders in a specialized mental healthcare facility in Pakistan: a randomized controlled trial

Syed Usman Hamdani (✉ syedusmanhamdani@gmail.com)
University of Liverpool Institute of Psychology Health and Society

Zill-e- Huma
Human Development Research Foundation

Aqsa Masood
Human Development Research Foundation

Kiana Zhou
Liverpool School of Tropical Medicine

Zainab Ahmed
Human Development Research Foundation

Huma Nazir
Human Development Research Foundation

Hania Amin
Institute of Psychiatry, WHO Collaborating Center for Mental Health Research, Benazir Bhutto Hospital

Parveen Akhtar
Human Development Research Foundation

Richard Bryant
University of New South Wales

Katie Dawson
University of New South Wales

Mark van Ommeren
World Health Organization

Duolao Wang
Liverpool School of Tropical Medicine

Atif Rahman
University of Liverpool Institute of Psychology Health and Society

Fareed Aslam Minhas
Institute of Psychiatry, WHO Collaborating Center for Mental Health Research and Training, Benazir Bhutto Hospital
Research

Keywords: Low intensity psychological intervention, Cognitive Behavioral Therapy, Specialized mental health facility, Common Mental Disorders, Depression, Anxiety

DOI: https://doi.org/10.21203/rs.3.rs-26484/v2

License: ☐️️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** In many low resource settings, the provision of government mental health care services is limited to specialized psychiatry units in urban hospital care facilities, where the most common treatment for common mental disorders (CMDs) is pharmacotherapy, occasionally with adjunct nonspecific psychological support. We aimed to evaluate the effectiveness of adding a low intensity, psychological intervention, Problem Management Plus (PM+) for CMDs into routine care in a specialized mental health care facility in Pakistan.

**Methods:** A two arm, single-blind individual randomized controlled trial (RCT) was carried out with adults (N=192), referred for psychological support by psychiatrists. The study participants were randomized (1:1) to PM+ plus Treatment as Usual (TAU) (n = 96) or TAU only (n = 96). The primary outcomes were symptoms of anxiety and depression, measured by the Hospital Anxiety and Depression Scale (HADS) and functional impairment as measured by WHO Disability Assessment Schedule (WHODAS 2.0) at 20 weeks after baseline.

**Results:** The analysis was done on intention-to-treat principle. The linear mixed model analysis showed that at 20 weeks after baseline, there was a significant reduction in symptoms of anxiety and depression (mean [SD], 16.23 [8.81] vs 19.79 [7.77]; AMD, -3.10; 95% CI, -0.26 to -5.76); \( p=0.03 \) and improvement in functioning (mean [SD], 22.94 [9.37] vs 27.37 [8.36]; AMD, -4.35; 95% CI, -1.45 to -7.24); \( p=0.004 \) in PM+ plus TAU versus TAU arm. The follow-up rate was 67% at primary end-point.

**Conclusions:** Specialized care facilities in LMICs may consider adding brief, evidence-based psychological treatments for CMDs to their routine care.

**Trial Registration:** Australian New Zealand Clinical Trials Registry, ACTRN12616000381482. Registered March 23, 2016

- Retrospectively registered, https://www.anzctr.org.au/Default.aspx/ ACTRN12616000381482

**Background**

Common mental disorders (CMDs), such as anxiety and depression, are one of the leading causes of disability globally \( (1) \). In low and middle-income countries (LMICs), the treatment gap for CMDs is more than 90% \( (2) \). Despite the wide-spread recognition of this gap for CMDs in LMICs, the provision of government mental health care services is usually limited to specialized psychiatry units, located in hospital care facilities \( (3) \). Mental health needs are evident in Pakistan, which has been affected by chronic adversity in the form of socio-political instability, economic uncertainty, regional conflict and dislocation. These events have led to increased levels of psychological and social suffering, including a high prevalence of mental disorders in Pakistan \( (4, 5) \).
A number of psychological intervention manuals – mainly based on cognitive behavioral and interpersonal psychotherapy - have been developed and proven effective for treating CMDs in primary health care and community settings in LMICs (6-10) and meta-analyses suggest that such interventions are as effective as pharmacotherapy (11). The World Health Organization (WHO) recommends that both anti-depressants and psychological interventions should be available to people with depression (12). A brief, multicomponent behavioral WHO intervention called Problem Management Plus (PM+) was developed for the management of CMDs in settings affected by adversity (13). There have been multiple trials of PM+ delivered in individual and group formats (9, 10, 14). However, these studies have focused on evaluating the effectiveness of PM+ to reduce CMDs in primary health care and community settings.

The mainstay of treatment for CMDs in many psychiatric units is pharmacotherapy (15), occasionally with adjunct nonspecific psychological support. It is thus valuable to evaluate whether evidence-based psychological interventions can be effectively added in routine specialist health context to reduce CMDs for people with anxiety or depression.

**Methods**

This study aimed to evaluate the effectiveness of adding PM+ for CMDs to routine care in a specialized mental health care facility in Pakistan. We hypothesized that PM+ in combination with Treatment-as-Usual (TAU) will be superior compared to TAU alone, to reduce the symptoms of depression and anxiety measured with Hospital Anxiety and Depression Scale (HADS) total score at 20 weeks after baseline.

**Design**

We conducted a single-blind individual randomized controlled trial (RCT) to evaluate the effectiveness of PM+ plus Treatment-as-Usual (TAU) versus TAU alone in the treatment of CMDs in patients presenting in the out-patient department of Institute of Psychiatry, Rawalpindi, Pakistan. The study was conducted over the duration of 12 months. Ethical approval of the study was obtained from the Institutional Review and Ethics Board of the Rawalpindi Medical University and Allied Hospitals Rawalpindi (ethical approval certificate number ERC/RMU/01/06/2015). The full trial protocol is available online (16). Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12616000381482. Registered Retrospectively on March 23, 2016.

**Study settings**

The participants were recruited from the Institute of Psychiatry (IoP), WHO Collaborating Centre for Mental Health Research and Training, Benazir Bhutto Hospital-the public sector tertiary care hospital in Rawalpindi, Pakistan. IoP is the hub of mental health policy, services, training and research in Pakistan. It is the specialist referral facility for the patients with mental health problems presenting in the primary and secondary health care facilities in the north of Pakistan. Patient services include in-patients and outpatient services which are led by teams comprising of consultant psychiatrists and psychologists, trainee psychiatrists and psychologists, social workers and interns.
Participants

The target population for this study was adult (age 18-60 years) outpatient department attendees, referred for psychological support for depression, anxiety and stress related conditions by psychiatrists after clinical evaluation who (a) scored above 2 on a screening questionnaire for psychological distress (General Health Questionnaire-12; GHQ-12; (17, 18) and (b) scored above 16 on a screening questionnaire for functional impairments (WHO Disability Assessment Schedule – WHODAS 2.0) (19). As PM+ is not suitable for the treatment of severe mental health problems (including psychosis or risk of suicide) (13), participants with imminent risk of suicide, severe mental disorder (e.g. psychotic disorders, substance dependence), or severe cognitive impairment (e.g. severe intellectual disability, dementia) as assessed by psychiatrists, were excluded from the study.

Interventions

Problem Management plus (PM+)

The WHO PM+ intervention (individual version) (13) is based on established principles of problem solving and behavioral techniques and is delivered in five weekly face-to-face sessions administered on an individual basis. The average duration of each session is 90 minutes. The two key features of WHO PM+ program are (a) the program takes a task-shifting approach where non-specialists (workers without a professional license specific for mental health care such as, in Pakistan, psychology graduates, nurses and community volunteers) can deliver this program to adults experiencing common mental health problems (e.g. anxiety, stress, depression and grief) (b) it is trans-diagnostic - it addresses a range of symptoms for common mental disorders and does not require an expert diagnosis of condition to qualify treatment. PM+ providers in this study had a master's degree (16 years of education) in psychology and received eight days training in PM+ by the master trainer followed by fortnightly supervision meetings with the master trainer.

Treatment-as-Usual (TAU)

Treatment-as-usual in the outpatient’s department consists of an initial assessment by trainee psychiatrists followed by an expert consultation on the case by consultant psychiatrist. The main stay of treatment is pharmacotherapy and psychological support where needed. A psychological support session comprises of brief semi-structured psycho-education sessions for patients with depression and anxiety symptoms and training in anger and stress management strategies such as breathing exercises. A complete record of services received by trial participants in both study arms was obtained using the Client Services Receipt Inventory (CSRI).

Primary outcomes

The primary outcomes were (a) symptoms of anxiety and depression measured using the Hospital Anxiety and Depression Scale (HADS) (20, 21) and (b) functional impairment as measured by WHODAS 2.0 (22) at 20 weeks after baseline.
a) The HADS is a well-established 14-item scale consisting of two subscales: HADS-A (anxiety, seven items, and scores range from 0–21) and HADS-D (depression, seven items, scores range from 0–21), where higher scores indicate more anxiety and/or depression. In our study, we used a previously validated Urdu version of HADS (20).

b) Functional impairment was assessed using the 12-item WHO Disability Assessment Schedule (WHODAS 2.0) (22). WHODAS 2.0 assesses participants’ health-related difficulties in the level of functioning in six domains of life (understanding and communicating; moving and getting around; attending to one's hygiene, dressing, eating and staying alone; interacting with other people; domestic responsibilities, leisure, work and school and joining in community activities, participating in society) over the past 30 days. WHODAS 2.0 has been extensively used in different populations and health conditions including mental health and established itself as gold standard to measure functioning (23).

All the study tools were administered in local (i.e. Urdu) language and have been previously used in the similar settings of Pakistan (9, 10, 24).

An independent assessment team, trained in the ethical conduct of research and assessments and blinded to the allocation status of the trial participants, conducted baseline and post-intervention assessments.

**Secondary outcomes**

The secondary clinical outcomes included;

The Patient Health Questionnaire-9 (PHQ-9), which is a 9-item instrument measuring presence and severity of depression during the past 2-weeks on a 4-point Likert scale ranging from ‘not at all’ to ‘nearly every day’. The PHQ-9 total severity score ranges from 0 to 27 (25). Higher scores indicate more severe depression. We used the previously validated Urdu version of PHQ-9 (26, 27).

The 17 item Post Traumatic Stress Symptoms-Checklist (PCL-C) was used to measure DSM-IV based posttraumatic stress disorder symptoms. The participants are asked to rate their responses on a 5-point scale during the past week. The PCL-C has been used previously in Pakistan (28) and found to have good psychometric properties (Mushtaq, unpublished data, 2013). In the current study, we changed the reporting time of PCL from last month to last week to enhance the sensitivity of tool to detect change at the 3 months’ post-intervention.

Psychological profile outcome (PSYCHLOPS)- (29) assesses personally identified problems. It consists of four questions that encompass three domains: problems (2 questions), functioning (1 question) and wellbeing (1 question). Participants are asked to give free text responses to the problem and function domains. Responses are scored on an ordinal 6-point scale producing a maximum score of 20 (6 points per domain). The PSYCHLOPs version administered at post-treatment and follow-up also includes an overall evaluation question (determining self-rated outcome ranging from ‘much better’ to ‘much worse’).
in relation to the identified problem. PSYCHLOPS has been validated in primary care populations across several countries (30, 31).

The Multidimensional Scale of Perceived Social Support (MSPSS) (32) aims to measure perceived social support. It includes 12 items which cover three dimensions: support from family, friends and significant other. Each item is rated on a 7-point Likert-scale (1 = very strongly disagree; 7 = very strongly agree). A total score is calculated by summing the responses of all items (range 12–84) with higher scores indicating higher levels of perceived social support. The MSPSS has been validated in Urdu. (33)

Services accessed by participants were recorded using the Client Services Receipt Inventory (CSRI). The CSRI was developed for the collection of data on service utilization and related characteristics of people with mental disorders, as the basis for calculating the costs of care for mental health cost-effectiveness research (34). It has been previously used in Pakistan and India (34, 35).

**Procedure**

Patients who presented at the out-patients’ departments between July 2015 and November 2016 for treatment of CMDs were evaluated by a psychiatrist. After clinical evaluation, if the psychiatrist decided psychological support was indicated, s/he introduced the study and took verbal consent for participation in the study. Written informed consent was obtained from eligible participants by the study coordinator. Participants were randomized to intervention or control arm on a 1:1 basis using computerized software by an independent researcher. The allocation concealment was ensured by keeping random sequence in sequentially numbered, opaque, sealed envelopes, at the off-site center. The intervention arm participants received a total of five weekly individual sessions of PM+ program by PM+ providers and TAU from the psychiatrists/psychologists. The control arm participant received TAU from the psychiatrist/psychologists at the mental health facility. Post-treatment assessments were carried out at two-time points a) seven-week after baseline and b) 20 weeks after baseline. Participants who developed severe psychiatric problems (e.g., psychosis, imminent suicidality) at follow-up were referred to psychiatrists for specialist care (n=3).

**Statistical analysis**

Sample size calculation was based on a multicenter study of culturally-adapted cognitive behavioral therapy (CBT)-based intervention conducted in Pakistan that used the HADS as the primary outcome measure (36). A two-point reduction in HADS depression score between the intervention and control arm is considered to be clinically relevant (36). With \( p < .05 \) and 90% power, a total of 96 participants were needed. Accounting for an expected drop-out rate of 50%, the total sample size was 192 participants, who were equally randomized to PM+ (n = 96) and TAU (n = 96).

The data was analyzed using an Intent-To-Treat (ITT) analysis approach. The primary outcome was summarized using number of participants (n), means and standard deviations (SD). To estimate the treatment effect, a linear mixed model was employed for the primary endpoint analysis, which had
treatment, visit, interaction between treatment and visit as fixed effects, baseline measurement of primary endpoint as covariate, and subject as random effects. The mean difference between two treatment arms at each visit/time together with its 95% confidence interval was derived from the mixed model. Covariate-adjusted mixed model of primary endpoint (20 weeks after baseline) was also performed by adding pre-specified covariates at baseline into the above model. Secondary continuous outcomes were analyzed in a similar way. Missing data was treated as missing at random in the mixed model analysis and no imputation of primary and secondary endpoints was made. All analyses were performed using SAS 9.3.

Results

489 patients were assessed for eligibility. 192 participants, who met the inclusion criteria and provided informed consent were enrolled in the trial and randomly allocated (1:1) to PM+ plus TAU (n=96) and TAU arms (n=96) [Figure 1]. The follow-up rate for primary outcome at the primary endpoint (20 weeks after baseline) was 64.5% (62 of 96 participants) in the intervention arm and 69.79% (67 of 96 participants) in the control arm. There were no significant differences between the two arms in demographic characteristics and symptom scores at baseline. The mean (±SD) age of the participants was 34.05 (±10.47) years. 68% (128/192) of the participants were females.

[Table 1]
Table 1
Demographic characteristics of the study participants (n, %)

| Variable                        | PM + N (%) | TAU N (%) | Total (N = 192) |
|---------------------------------|------------|-----------|-----------------|
|                                 | (n = 96)   | (n = 96)  |                 |
| Age (mean ± SD)                 | 33.03 ± 9.94 | 35.07 ± 10.95 | 34.05 ± 10.47 |
| Gender                          |            |           |                 |
| Male                            | 32 (33.3)  | 28 (29.2) | 60 (31.9)       |
| Female                          | 62 (64.6)  | 66 (68.8) | 128 (68)        |
| Education                       |            |           |                 |
| Uneducated                      | 15 (15.6)  | 25 (26)   | 40 (20.8)       |
| Completed primary (grade 5)     | 20 (20.8)  | 12 (12.5) | 32 (16.7)       |
| Completed middle (grade 8)      | 9 (9.4)    | 13 (13.5) | 22 (11.5)       |
| Completed matriculate (grade 10)| 16 (16.7)  | 14 (14.6) | 30 (15.6)       |
| Completed College and University (grade 11–16) | 36 (37.5) | 30 (31.3) | 66 (34.4) |
| Marital status                  |            |           |                 |
| Never married                   | 28 (29.8)  | 19 (19.8) | 47 (24.5)       |
| Currently married               | 61 (63.5)  | 69 (71.9) | 130 (67.7)      |
| Separated                       | 1 (1.0)    | 2 (2.1)   | 3 (1.6)         |
| Divorced                        | 3 (3.1)    | 2 (2.1)   | 5 (2.6)         |
| Widowed                         | 3 (3.1)    | 4 (4.2)   | 7 (3.6)         |
| Employment status               |            |           |                 |
| Employed                        | 31 (32.3)  | 26 (27.1) | 57 (29.7)       |
| Not employed                    | 65 (67.7)  | 70 (72.9) | 135 (70.3)      |
| Occupation                      |            |           |                 |
| Paid work                       | 24 (25.8)  | 20 (21.3) | 44 (22.9)       |
| Self-employed                   | 10 (10.8)  | 8 (8.5)   | 18 (9.4)        |
| Student                         | 2 (2.2)    | 3 (3.2)   | 5 (2.6)         |
| Keeping house/homemaker         | 14 (15.1)  | 18 (19.1) | 32 (16.7)       |
| Retired                         | 0 (0.0)    | 2 (2.1)   | 2 (1)           |
| Unemployed (health reasons)     | 2 (2.2)    | 1 (1.1)   | 3 (1.6)         |
58% of participants attended 3 or more sessions of PM+ intervention. The mean number of intervention sessions attended by trial participants was 2.84 (± 2.16). Each session lasted for an average of 90 minutes. The quality of intervention delivery was assessed by completing a self-check for each session by the PM+ providers, supported by peer-supervision and fortnightly supervisions with the mental health specialist via Skype. In terms of medication, 36/64 (56%) participants in PM+ and 49/67 (73%) participants in TAU reported receiving a prescription of psychotropic medicines.

[Table 4]
Table 4

*Health services utilization across two arms after 20-weeks after baseline

| Health service providers accessed | PM+ (f) | TAU (f) |
|----------------------------------|---------|---------|
| Psychiatrist                     | 45      | 49      |
| Specialist doctor                | 21      | 33      |
| General doctor                   | 16      | 11      |
| Pharmacist                        | 1       | 2       |
| Traditional healer               | 2       | 1       |
| Other mental health worker       | 2       | -       |

**Number of visits**

|          | PM+ (f) | TAU (f) |
|----------|---------|---------|
| 3 visits | 8       | 13      |
| 2 visits | 30      | 32      |
| 1 visit  | 54      | 65      |

**Location**

|                      | PM+ (f) | TAU (f) |
|----------------------|---------|---------|
| Public hospital      | 47      | 53      |
| Private hospital     | 11      | 6       |
| Local health centre  | -       | 5       |

**Reasons for visit**

| Reason for visit                                                                 | PM+ (f) | TAU (f) |
|----------------------------------------------------------------------------------|---------|---------|
| Follow-up visit for treatment of depression or anxiety problems                  | 50      | 60      |
| Sleep problems                                                                   | 10      | 13      |
| Acute aggravation of mental health problems                                      | 6       | 13      |
| Other mental health problems e.g. maternal/perinatal mental health condition     | 15      | 16      |
| Infectious diseases and injuries                                                | 2       | 2       |

**Medications**

| Medication                        | PM+ (f) | TAU (f) |
|-----------------------------------|---------|---------|
| A. Antidepressants (n = 58)       |         |         |
| - SSRIs                           | 22      | 31      |
| - TCAs                            | 2       | 3       |

*Due to multiplicity of contacts with service providers and treatments received, the table reports frequency of contacts and prescribed treatment; **3 in intervention and 2 participants in TAU were hospitalized during the study.*
| Health service providers accessed                              | PM+ (f) | TAU (f) |
|---------------------------------------------------------------|---------|---------|
| B. Anxiolytics                                                | 8       | 9       |
| C. Mood stabilizers                                           | 2       | 1       |
| D. Anti-psychotics                                            | 2       | 5       |
| E. Multi-vitamins                                             | 8       | 5       |
| F. Analgesics                                                 | 4       | 3       |
| G. Others (anti-hypertensive, anti-diabetic, thyroid related)  | 6       | 9       |
| **Average duration of consultation (in minutes) M(SD); min-max** | 7.62 (± 2.57); 3–15 | 8.85 (± 3.99); 2–20 |
| **Average consultation fee paid (in PKR) M(SD); min-max**     | 32 (± 129.9); 0-700 | 3.10 (± 14.79); 0-100 |

*Due to multiplicity of contacts with service providers and treatments received, the table reports frequency of contacts and prescribed treatment; **3 in intervention and 2 participants in TAU were hospitalized during the study.

Seven-week after baseline, the intervention arm had significantly lower scores on HADS (mean [SD], 16.72[8.44] vs 21.0 [7.88]; adjusted mean difference [AMD], 4.35; 95% CI, 1.71 to 6.99). At 20 weeks after baseline, the intervention arm had significantly lower scores than the control arm (mean [SD], 16.23 [8.81] vs 19.79 [7.77]; AMD, 3.10; 95% CI, 0.26 to 5.76). Seven -week after baseline, the intervention group had significantly lower scores on HADS-A (mean [SD], 8.56 [5.00] vs 11.08 [4.90]; AMD, 2.41; 95% CI, 0.77 to 4.04) and HADS-D (mean [SD], 8.16 [4.17] vs 9.92 [4.37]; AMD, 1.85; 95% CI, 0.41 to 3.29). At 20 weeks after baseline, the intervention arm had significantly lower scores than the control arm on HADS-A (mean [SD], 8.17 [5.12] vs 10.12 [4.79]; AMD, 1.69; 95% CI, -0.02 to 3.41), however, there was no significant difference between two arms on HADS-D (mean [SD], 8.04 [4.89] vs 9.67 [3.94]; AMD, 1.30; 95% CI, -0.21 to 2.81).

[Table 2]
Table 2
Summary statistics and results from mixed-model analysis of primary and secondary outcomes

| Primary and secondary outcomes | Visit       | PM+ (N = 96) | TAU (N = 96) | Difference in Least Squares Mean (95% CI) | P-value |
|--------------------------------|-------------|--------------|--------------|------------------------------------------|---------|
|                                | N | M (SD) | N | M (SD) |                                           |         |
| HADS Anxiety                   | Pre-Treatment | 95 | 13.44 (3.67) | 96 | 12.90 (4.02) | -2.41 (-4.04 to -0.77) | 0.004   |
|                                | Post-Treatment | 73 | 8.56 (5.00) | 73 | 11.08 (4.90) | 1.69 (3.41 to 0.02) | 0.05    |
|                                | Follow-Up | 62 | 8.17 (5.12) | 67 | 10.12 (4.79) | -1.69 (-3.41 to 0.02) | 0.09    |
| HADS Depression                | Pre-Treatment | 95 | 12.18 (3.99) | 96 | 10.80 (3.72) | -1.36 (-3.29 to -0.41) | 0.01    |
|                                | Post-Treatment | 73 | 8.16 (4.17) | 73 | 9.92 (4.37) | -1.85 (-3.29 to -0.41) | 0.01    |
|                                | Follow-Up | 62 | 8.04 (4.89) | 67 | 9.67 (3.94) | -1.30 (-2.81 to 0.21) | 0.09    |
| HADS                           | Pre-Treatment | 95 | 25.62 (6.61) | 96 | 23.70 (6.07) | -1.66 (-3.29 to -0.41) | 0.01    |
|                                | Post-Treatment | 73 | 16.72 (8.44) | 73 | 21.00 (7.88) | -4.35 (-6.99 to -1.71) | 0.002   |
|                                | Follow-Up | 62 | 16.23 (8.81) | 67 | 19.79 (7.77) | -3.56 (-5.76 to -1.36) | 0.03    |
| WHODAS                         | Pre-Treatment | 96 | 33.41 (7.17) | 96 | 32.77 (7.77) | -0.64 (-1.28 to 0.00) | 0.07    |
|                                | Post-Treatment | 74 | 25.20 (8.97) | 74 | 28.41 (8.19) | -3.21 (-6.38 to -0.04) | 0.01    |
|                                | Follow-Up | 62 | 22.94 (9.73) | 67 | 27.37 (8.36) | -4.43 (-7.24 to -1.62) | 0.004   |

TAU = Treatment as usual; PM+ = Problem Management Plus; HADS = Hospital Anxiety and Depression Scales (subscale score range: 0–21; higher scores indicate elevated anxiety or depression, respectively); WHODAS = WHO Disability Adjustment Scale (total score range: 0–48; higher scores indicate more severe impairment); PCL = Posttraumatic Stress Disorder Checklist (total score range: 17–85; higher scores indicate more severe PTSD severity); PHQ = Patient Health Questionnaire (total score range: 0–27; higher scores indicate more severe depression; PSYCHLOPS = Psychological Outcome Profiles (total score range: 0–20; higher scores indicate poorer outcome)

Post-treatment = 7-week after baseline; Follow-up = 20 weeks after baseline
|                          | n   | mean (SD)          | n   | mean (SD)          |
|--------------------------|-----|--------------------|-----|--------------------|
| **PCL**                  |     |                    |     |                    |
| Pre-Treatment            | 96  | 49.78 (13.99)      | 96  | 49.86 (13.66)      |
| Post-Treatment           | 61  | 39.90 (15.89)      | 63  | 42.35 (15.73)      |
|                          |     | -2.69 (-8.08 to 2.70) | 0.32 |
| Follow-Up                | 61  | 32.93 (14.21)      | 64  | 39.08 (15.75)      |
|                          |     | -5.39 (-10.76 to -0.02) | 0.05 |
| **PHQ**                  |     |                    |     |                    |
| Pre-Treatment            | 96  | 15.09 (5.17)       | 96  | 15.04 (4.99)       |
| Post-Treatment           | 53  | 9.79 (6.71)        | 54  | 11.76 (6.51)       |
|                          |     | -2.18 (-4.65 to 0.29) | 0.08 |
| Follow-Up                | 61  | 7.16 (6.23)        | 63  | 10.29 (6.79)       |
|                          |     | -2.91 (-5.22 to -0.60) | 0.01 |
| **Days of these**        |     |                    |     |                    |
| difficulties present     |     |                    |     |                    |
| Pre-Treatment            | 92  | 20.93 (9.61)       | 93  | 20.89 (8.51)       |
| Post-Treatment           | 66  | 13.98 (10.45)      | 67  | 18.10 (10.21)      |
|                          |     | -3.93 (-7.44 to -0.43) | 0.03 |
| Follow-Up                | 60  | 13.88 (11.17)      | 64  | 16.67 (9.59)       |
|                          |     | -2.80 (-6.40 to 0.80) | 0.13 |
| **Days of total**        |     |                    |     |                    |
| disability              |     |                    |     |                    |
| Pre-Treatment            | 91  | 11.22 (9.78)       | 92  | 10.82 (9.47)       |
| Post-Treatment           | 65  | 5.03 (7.15)        | 67  | 7.82 (9.03)        |
|                          |     | -2.62 (-5.29 to 0.06) | 0.06 |
| Follow-Up                | 60  | 5.82 (7.34)        | 64  | 8.00 (7.82)        |
|                          |     | -1.71 (-4.46 to 1.03) | 0.22 |
| **Days of activity**     |     |                    |     |                    |
| reduce                   |     |                    |     |                    |
| Pre-Treatment            | 90  | 14.14 (10.26)      | 92  | 12.97 (10.19)      |
| Post-Treatment           | 65  | 8.22 (8.40)        | 67  | 11.19 (9.58)       |
|                          |     | -2.72 (-5.92 to 0.49) | 0.10 |
| Follow-Up                | 60  | 8.35 (9.57)        | 64  | 10.20 (9.69)       |
|                          |     | -1.92 (-5.22 to 1.38) | 0.25 |

TAU = Treatment as usual; PM + = Problem Management Plus; HADS = Hospital Anxiety and Depression Scales (subscale score range: 0–21; higher scores indicate elevated anxiety or depression, respectively); WHODAS = WHO Disability Adjustment Scale (total score range: 0–48; higher scores indicate more severe impairment); PCL = Posttraumatic Stress Disorder Checklist (total score range: 17–85; higher scores indicate more severe PTSD severity); PHQ = Patient Health Questionnaire (total score range: 0–27; higher scores indicate more severe depression; PSYCHLOPS = Psychological Outcome Profiles (total score range: 0–20; higher scores indicate poorer outcome)

Post-treatment = 7-week after baseline; Follow-up = 20 weeks after baseline
Descriptive statistics

| n, mean (SD)       | Perceived social support | PSYCHLOPS       |
|-------------------|--------------------------|----------------|
|                   | Pre-Treatment            | Post-Treatment | Follow-Up       |
|                   | 96                       | 73             | 61             | 96               | 95               |
|                   | 51.92 (16.60)            | 55.53 (17.70)  | 56.61 (17.35)  | 15.39 (3.65)     | 9.31 (5.68)      |
|                   | 96                       | 74             | 65             | 14.94 (3.77)     | 69               |
|                   | 52.74 (17.11)            | 51.43 (18.03)  | 52.57 (14.70)  | 14.94 (3.77)     | 11.55 (5.01)     |
|                   |                          | 3.85 (-4.55 to 9.25) | 2.24 (-3.42 to 7.90) | -2.40 (-4.19 to -0.60) | -1.63 (-3.51 to 0.24) |
|                   |                          | 0.16           | 0.43           | 0.009            | 0.09            |

TAU = Treatment as usual; PM + = Problem Management Plus; HADS = Hospital Anxiety and Depression Scales (subscale score range: 0–21; higher scores indicate elevated anxiety or depression, respectively); WHODAS = WHO Disability Adjustment Scale (total score range: 0–48; higher scores indicate more severe impairment); PCL = Posttraumatic Stress Disorder Checklist (total score range: 17–85; higher scores indicate more severe PTSD severity); PHQ = Patient Health Questionnaire (total score range: 0–27; higher scores indicate more severe depression; PSYCHLOPS = Psychological Outcome Profiles (total score range: 0–20; higher scores indicate poorer outcome)

Post-treatment = 7-week after baseline; Follow-up = 20 weeks after baseline

Seven-week after baseline, the intervention arm had significantly lower scores on WHODAS 2.0 (mean [SD], 25.20 [8.97] vs 28.41 [8.19]; AMD, 3.16 95% CI, 0.85 to 6.38). At 20 weeks after baseline, the difference of WHODAS 2.0 scores between intervention and control arm was sustained (mean [SD], 22.94 [9.37] vs 27.37 [8.36]; AMD, 4.35; 95% CI, 1.45 to 7.24).

At 20 weeks after baseline, there was a significant reduction in the level of posttraumatic stress in the intervention arm (mean [SD], 32.93 [14.21] compared to the control arm 39.08 [15.75]; AMD, 5.39; 95% CI, 0.02 to 10.76). Similarly, there was significant reduction in the symptoms of depressive disorder in the intervention arm (PHQ-9: mean [SD], 7.16 [6.23] compared to the control arm 10.29 [6.79]; AMD, 2.91; 95% CI, 0.60 to 5.22) at 20 weeks after baseline. However, no significant differences were observed in the scores of PSYCHLOPS (mean [SD], 8.98 [5.93] vs 10.62 [4.99]; AMD, 1.63; 95% CI, -0.24 to 3.51), and social support (mean [SD], 56.61 [17.35] vs 52.57 [14.70]; AMD, -2.24; 95% CI, -7.90 to 3.42) between the two arm at 20 weeks after baseline.

The findings from covariate adjusted analysis showed that, after controlling for the baseline measurements (i.e. age, gender, severity on HADS), there was significant improvement in the intervention arm than TAU arm at both seven and 20 weeks after baseline in the clinical outcome measures.
Table 3
Summary results from post hoc Mixed-Model Analysis of Primary and Secondary Outcomes, with baseline measurement (i.e. age, gender, HADS) included as covariate

| Primary and secondary outcomes | Visit          | Difference in Least Squares Mean for Intervention vs Treatment as Usual (95% CI) | P value |
|-------------------------------|---------------|---------------------------------------------------------------------------------|---------|
| HADS Anxiety                  | Pre-Treatment |                                                                                 |         |
|                               | Post-Treatment| -2.67 (-4.32 to -1.03)                                                          | 0.002   |
|                               | Follow-Up     | -1.84 (-3.56 to -0.13)                                                           | 0.04    |
| HADS Depression               | Pre-Treatment |                                                                                 |         |
|                               | Post-Treatment| -1.98 (-3.41 to -0.55)                                                           | 0.007   |
|                               | Follow-Up     | -1.43 (-2.92 to 0.07)                                                            | 0.06    |
| HADS                          | Pre-Treatment |                                                                                 |         |
|                               | Post-Treatment| -4.65 (-7.27 to -2.03)                                                           | 0.0006  |
|                               | Follow-Up     | -3.20 (-5.92 to -0.48)                                                           | 0.02    |
| WHO DAS                       | Pre-Treatment |                                                                                 |         |
|                               | Post-Treatment| -3.81 (-6.59 to -1.04)                                                           | 0.008   |
|                               | Follow-Up     | -4.44 (-7.34 to -1.55)                                                           | 0.003   |
| PCL                           | Pre-Treatment |                                                                                 |         |
|                               | Post-Treatment| -3.30 (-8.71 to 2.12)                                                            | 0.23    |
|                               | Follow-Up     | -5.17 (-11.08 to -0.33)                                                           | 0.04    |
| PHQ                           | Pre-Treatment |                                                                                 |         |
|                               | Post-Treatment| -2.51 (-4.96 to -0.06)                                                           | 0.04    |

HADS = Hospital Anxiety and Depression Scale; WHODAS = WHO Disability Assessment Schedule 2.0; PCL = Post-traumatic stress disorder checklist; PHQ = Patient Health Questionnaire; PSYCHLOPS = Psychological Outcome Profile

Post-treatment = 7-week after baseline; Follow-up = 20 weeks after baseline
| Primary and secondary outcomes | Visit         | Difference in Least Squares Mean for Intervention vs Treatment as Usual (95% CI) | \( P \) value |
|--------------------------------|---------------|----------------------------------------------------------------------------------|---------------|
|                                | Follow-Up     | -3.04 (-5.32 to -0.76)                                                           | 0.01          |
| Days of these difficulties present | Pre-Treatment |                                                                                   |               |
|                                | Post-Treatment| -4.33 (-7.90 to -0.77)                                                           | 0.02          |
|                                | Follow-Up     | -2.84 (-6.47 to 0.79)                                                            | 0.12          |
| Days of total disability       | Pre-Treatment |                                                                                   |               |
|                                | Post-Treatment| -2.51 (-5.18 to 0.15)                                                            | 0.06          |
|                                | Follow-Up     | -1.69 (-4.41 to 1.02)                                                             | 0.22          |
| Days of activity reduce        | Pre-Treatment |                                                                                   |               |
|                                | Post-Treatment| -3.15 (-6.41 to 0.10)                                                            | 0.06          |
|                                | Follow-Up     | -1.95 (-5.27 to 1.37)                                                             | 0.25          |
| Perceived social support       | Pre-Treatment |                                                                                   |               |
|                                | Post-Treatment| 4.45 (-1.05 to 9.95)                                                              | 0.11          |
|                                | Follow-Up     | 2.52 (-3.22 to 8.27)                                                              | 0.39          |
| PSYCHLOPS                       | Pre-Treatment |                                                                                   |               |
|                                | Post-Treatment| -2.58 (-4.39 to -0.77)                                                            | 0.006         |
|                                | Follow-Up     | -1.66 (-3.54 to 0.23)                                                             | 0.08          |

HADS = Hospital Anxiety and Depression Scale; WHODAS = WHO Disability Assessment Schedule 2.0; PCL = Post-traumatic stress disorder checklist; PHQ = Patient Health Questionnaire; PSYCHLOPS = Psychological Outcome Profile

Post-treatment = 7-week after baseline; Follow-up = 20 weeks after baseline

**Discussion**

The addition of PM+ intervention to routine care in the specialist mental health facility in Pakistan led to improvements in symptoms of anxiety, depression, post-traumatic stress, and functioning at seven and
20 weeks after baseline compared to routine care alone. PM+ involves evidence-based psychological strategies (including problem solving, stress management, behavioral activation, and strengthening social support) that seek to reduce the symptoms of anxiety and depression (13). It has been evaluated with adults affected by adversity and experiencing psychological distress in number of studies conducted in low resource contexts and settings, globally (9, 10, 14, 24). The results of current study demonstrates that PM+ intervention delivered by non-specialists, can improve the symptoms of anxiety and depression among outpatient adults in specialist mental health care facility.

A key strength of the current study is that, we compared two active interventions for treatment of CMDs in a specialist mental health care facility in Pakistan (PM+ plus routine care versus routine care alone). The results demonstrated noticeable gains in treatment of anxiety and depression symptoms with addition of PM+ to ongoing routine care that consisted of pharmacotherapy in most cases. The findings of our study are supported by a systematic review and meta-analysis of literature by Cuijpers et al (2014) (11), which concluded that pharmacotherapy and psychotherapy both contribute equally and independently to the effects of combined treatment. Hence, PM+ may be a feasible and effective treatment option in out-patient psychiatry departments in LMICs, especially, where there are currently no defined psychological interventions available. However, further studies with placebo and combined pharmacotherapy and psychotherapy may be designed to understand the clinical advantage of combined treatment with PM+ intervention in tertiary care facilities.

Another strength of this study is the finding that non-specialists can effectively deliver the PM+ intervention to improve treatment outcomes for CMDs in a specialist mental health care facility in Pakistan. There is an urgent need to expand the mental health care workforce to meet the ever-increasing demand for evidence-based, holistic mental health services in low resource settings. Our study demonstrates that trans-diagnostic psychological intervention for CMDs can be delivered by the non-specialists such as psychology graduates, in out-patients psychiatry departments of low resource settings. Other studies in global mental health literature have reported similar findings where nurses, community health workers and peer volunteers have effectively delivered low intensity psychological interventions in low resource settings (6, 8, 9, 36-39).

It may be expected that the study participants at the tertiary care facility in the current study would have more severe depression and anxiety symptoms than the participants with the CMDs from community samples. Yet, the participants of present study in both study arms had baseline scores on symptoms of anxiety and depression similar to the other studies (9, 10, 14) that have evaluated the effectiveness of PM+ intervention in primary care and community settings; the drop in the symptoms scores on HADS in the present study as a result of intervention is comparatively less. These observations may be explained by a) reported high prevalence rates of psychological distress in humanitarian settings (4, 5, 40) and b) regression to mean phenomena. Natural remission seems to be more frequent in mild and moderate cases of depression (1, 37, 41); and c) exclusion of patients with severe symptoms of CMDs and in need of in-patient care from the present study.
Limitations

Results of our study demonstrate that the addition of PM+ intervention to routine care resulted in better treatment outcomes. However, there are a number of limitations which should be borne in mind while interpreting study findings. First, we were able to follow only 67% of the sample at 20 weeks after baseline. This high dropout rate is expected in public mental health facilities and was accounted for in sample size calculations. Second, while the literature reports long term gains of combined treatment, we were able to follow-up patients for 20 weeks only. Third, we collected data on the use of psychotropic medicines using the CSRI, which may be subject to recall bias of study participants. Further studies may benefit from including larger sample size, longer term follow-ups and objective data on the use of psychotropic medications (such as collecting data via hospital record). Lastly, the mean number of sessions attended by participants in the intervention arm was 2.86. Although, this is in keeping with compliance rates observed in the psychiatric outpatients’ department in public mental health facilities in low resource settings, this may raise concerns about the adequacy of the dose of intervention received by the trial participants. A meta-regression analysis conducted by Cuijpers et al (2013) observed a small correlation between number of therapy sessions and treatment effects and this association was not significant when the analysis adjusted for other characteristics of the studies (42). This evidence suggests that even few but meaningful clinical interactions can benefit symptom improvement in patients with CMDs.

Conclusions

Results of the study demonstrate that the addition of PM+ intervention to routine care resulted in better treatment outcome for the symptoms of anxiety and depression and improved functioning among out-patient attendees of a specialized mental health care facility in Pakistan. Specialized care facilities in LMICs may consider adding brief, evidence-based psychological treatments for CMDs to their routine care.

List Of Abbreviations

CBT: Cognitive Behavioral Therapy

CMDs: Common Mental Disorders

CSRI: Client Service Receipt Inventory

GHQ-12: General Health Questionnaire-12

HADS: Hospital Anxiety and Depression Scale

IoP: Institute of Psychiatry (IoP)

ITT: Intent-To-Treat
Declarations

Ethics approval and consent to participate

The ethical approval for the present study was obtained by Research and Ethical Committee, Rawalpindi Medical College and Allied Hospitals, Rawalpindi, Pakistan. Approval obtained on June 1, 2015.

Consent for publication

The consent for publication was obtained from all study participants at the time of enrollment.

Availability of data and materials

The dataset generated and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

The study was funded by World Health Organization (WHO), Department of Mental Health and Substance Abuse, Geneva, Switzerland and Human Development Research Foundation, Pakistan (HDRF).
Authors’ Contributors

SUH, ZeH, DW had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. SUH, AR, FAM, MoV, conceived the study. SUH, ZeH, AM, ZH, HN, HA, KZ, DW, RB, MoV were involved in acquisition, analysis, or interpretation of data. SUH, ZeH, AR and MoV drafted the manuscript. All authors were involved in drafting and commenting on the trial protocol. All authors read and approved the final manuscript.

Acknowledgements

We thank the staff at the Institute of Psychiatry (IoP), WHO Collaborating Centre for Mental health research and training, Rawalpindi, Pakistan, for their support in the conduct of the study, and the participants and their families for their voluntary participation.

Authors’ information

The authors alone are responsible for the views expressed in this article, which do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.

References

1. Whiteford H, Harris M, McKeon G, Baxter A, Pennell C, Barendregt J, et al. Estimating remission from untreated major depression: a systematic review and meta-analysis. Journal of Psychological Medicine. 2013;43(8):1569-85.

2. Thornicroft G, Chatterji S, Evans-Lacko S, Gruber M, Sampson N, Aguilar-Gaxiola S, et al. Undertreatment of people with major depressive disorder in 21 countries. The British Journal of Psychiatry. 2017;210(2):119-24.

3. Patel V, Chisholm D, Parikhs R, Charlson FJ, Degenhardt L, Dua T, et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities. The Lancet. 2016;387(10028):1672-85.

4. Husain N, Chaudhry I, Afridi MA, Tomson B, Creed F. Life stress and depression in a tribal area of Pakistan. The British Journal of Psychiatry. 2007;190(1):36-41.

5. Khan MN, Chiumento A, Dherani M, Bristow K, Sikander S, Rahman A. Psychological distress and its associations with past events in pregnant women affected by armed conflict in Swat, Pakistan: a cross sectional study. Conflict and Health. 2015;9(1):37.

6. Chibanda D, Weiss HA, Verhey R, Simms V, Munjoma R, Rusakaniko S, et al. Effect of a primary care–based psychological intervention on symptoms of common mental disorders in Zimbabwe: a randomized clinical trial. JAMA 2016;316(24):2618-26.

7. Patel V, Weobong B, Weiss HA, Anand A, Bhat B, Katti B, et al. The Healthy Activity Program (HAP), a lay counsellor-delivered brief psychological treatment for severe depression, in primary care in India: a randomised controlled trial. The Lancet. 2017;389(10065):176-85.
8. Bolton P, Bass J, Neugebauer R, Verdeli H, Clougherty KF, Wickramaratne P, et al. Group interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial. JAMA 2003;289(23):3117-24.

9. Rahman A, Hamdani SU, Awan NR, Bryant RA, Dawson KS, Khan MF, et al. Effect of a multicomponent behavioral intervention in adults impaired by psychological distress in a conflict-affected area of Pakistan: a randomized clinical trial. JAMA 2016;316(24):2609-17.

10. Rahman A, Khan MN, Hamdani SU, Chiumento A, Akhtar P, Nazir H, et al. Effectiveness of a brief group psychological intervention for women in a post-conflict setting in Pakistan: a single-blind, cluster, randomised controlled trial. The Lancet. 2019;393(10182):1733-44.

11. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF, 3rd. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56-67.

12. Dua T, Barui C, Patel AA, Tablante EC, Thornicroft G, Saxena S. Discussion of the updated WHO recommendations for mental, neurological, and substance use disorders. The Lancet Psychiatry. 2016;3(11):1008-12.

13. Dawson KS, Bryant RA, Harper M, Kuowei Tay A, Rahman A, Schafer A, et al. Problem Management Plus (PM+): a WHO transdiagnostic psychological intervention for common mental health problems. World Psychiatry. 2015;14(3):354-7.

14. Bryant RA, Schafer A, Dawson KS, Anjuri D, Mulili C, Ndogoni L, et al. Effectiveness of a brief behavioural intervention on psychological distress among women with a history of gender-based violence in urban Kenya: A randomised clinical trial. PLOS Medicine 2017;14(8):e1002371.

15. Some D, Edwards JK, Reid T, Van den Bergh R, Kosgei RJ, Wilkinson E, et al. Task shifting the management of non-communicable diseases to nurses in Kibera, Kenya: does it work? PLoS One. 2016;11(1):e0145634.

16. Hamdani SU, Ahmed Z, Sijbrandij M, Nazir H, Masood A, Akhtar P, et al. Problem Management Plus (PM+) in the management of common mental disorders in a specialized mental healthcare facility in Pakistan; study protocol for a randomized controlled trial. J International journal of mental health systems. 2017;11(1):40.

17. Goldberg D, Williams P, Williams P. A User's Guide to the General Health Questionnaire the General Health Questionnaire. Windsor: NFER^ Nelson Windsor: NFER^ Nelson. 1988.

18. Minhas F, Mubbashar M. Validation of General Health Questionnaire (GHQ-12) in primary care settings of Pakistan. Journal of College of Physicians and Surgeons Pakistan. 1996;6:133-6.

19. Üstün TB. Measuring health and disability: Manual for WHO disability assessment schedule WHODAS 2.0: World Health Organization; 2010.

20. Mumford D, Tareen I, Bajwa M, Bhatti M, Karim R. The translation and evaluation of an Urdu version of the Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica. 1991;83(2):81-5.

21. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica. 1983;67(6):361-70.
22. World Health Organization. Measuring health and disability: manual for WHO disability assessment schedule WHODAS 2.0. Geneva. 2010.

23. Federici S, Bracalenti M, Meloni F, Luciano JV. World Health Organization disability assessment schedule 2.0: An international systematic review. Disability and Rehabilitation. 2017;39(23):2347-80.

24. Khan MN, Hamdani SU, Chiumento A, Dawson K, Bryant RA, Sijbrandij M, et al. Evaluating feasibility and acceptability of a group WHO trans-diagnostic intervention for women with common mental disorders in rural Pakistan: a cluster randomised controlled feasibility trial. Epidemiology and psychiatric sciences. 2019;28(1):77-87.

25. Kroenke K, Spitzer R, Williams J. The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16:606-13.

26. Ahmer S, Faruqui RA, Aijaz A. Psychiatric rating scales in Urdu: A systematic review. BMC Psychiatry. 2007;7(1):59.

27. Husain N, Gater R, Tomenson B, Creed F. Comparison of the Personal Health Questionnaire and the Self Reporting Questionnaire in rural Pakistan. JPMA The Journal of the Pakistan Medical Association. 2006;56(8):366-70.

28. Khalily MT, Gul S, Mushtaq R, Jahangir SF. To examine delayed PTSD symptomatology over time among trauma survivors in Pakistan. Online Journal of Counselling and Education. 2012;1(1):1-11.

29. Ashworth M, Shepherd M, Christey J, Matthews V, Wright K, Parmentier H, et al. A client-generated psychometric instrument: The development of ‘PSYCHLOPS’. Counselling and Psychotherapy Research. 2004;4(2):27-31.

30. Czachowski S, Seed P, Schofield P, Ashworth M. Measuring psychological change during cognitive behaviour therapy in primary care: a polish study using ‘PSYCHLOPS’(psychological outcome profiles). PloS One. 2011;6(12):e27378.

31. Héðinsson H, Kristjánsdóttir H, Ólason DÞ, Sigurðsson JF. A validation and replication study of the patient-generated measure PSYCHLOPS on an Icelandic clinical population. European Journal of Psychological Assessment. 2013.

32. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The multidimensional scale of perceived social support. Journal of Personality Assessment. 1988;52(1):30-41.

33. Akhtar A, Rahman A, Husain M, Chaudhry IB, Duddu V, Husain N. Multidimensional scale of perceived social support: psychometric properties in a South Asian population. Journal of Obstetrics and Gynaecology Research. 2010;36(4):845-51.

34. Chisholm D, Knapp MRJ, Knudsen HC, Amaddeo F, Gaite L, Van Wijngaarden B. Client Socio-Demographic and Service Receipt Inventory-European Version: development of an instrument for international research. The British Journal of Psychiatry. 2000;177(39):s28-s33.

35. Buttorff C, Hock RS, Weiss HA, Naik S, Araya R, Kirkwood BR, et al. Economic evaluation of a task-shifting intervention for common mental disorders in India. Bulletin of the World Health Organization. 2012;90(11):813-21.
36. Naeem F, Gul M, Irfan M, Munshi T, Asif A, Rashid S, et al. Brief culturally adapted CBT (CaCBT) for depression: A randomized controlled trial from Pakistan. Journal of Affective Disorders. 2015;177:101-7.

37. Sikander S, Ahmad I, Atif N, Zaidi A, Vanobberghen F, Weiss H, et al. Delivering the Thinking Healthy Programme for perinatal depression through volunteer peers: a cluster randomised controlled trial in Pakistan. Lancet Psychiatry. 2019;6:128-39.

38. Patel V, Weiss HA, Chowdhary N, Naik S, Pednkar S, Chatterjee S, et al. Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial. The Lancet. 2010;376(9758):2086-95.

39. Murray LK, Familiar I, Skavenski S, Jere E, Cohen J, Imasiku M, et al. An evaluation of trauma focused cognitive behavioral therapy for children in Zambia. Child Abuse & Neglect. 2013;37(12):1175-85.

40. Steel Z, Chey T, Silove D, Marnane C, Bryant RA, Van Ommeren M. Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis. JAMA 2009;302(5):537-49.

41. Posternak MA, Miller I. Untreated short-term course of major depression: a meta-analysis of outcomes from studies using wait-list control groups. Journal of Affective Disorders. 2001;66(2-3):139-46.

42. Cuijpers P, Huibers M, Ebert DD, Koole SL, Andersson G. How much psychotherapy is needed to treat depression? A metaregression analysis. Journal of affective disorders. 2013;149(1-3):1-13.

Figures
489 patients were assessed for eligibility. 192 participants, who met the inclusion criteria and provided informed consent were enrolled in the trial and randomly allocated (1:1) to PM+ plus TAU (n=96) and TAU arms (n=96).